Atropine
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Atropine: From Bradycardia to Migraine Disorder
One-Sentence Summary
Atropine is a classic muscarinic receptor antagonist with established clinical uses in bradycardia management, organophosphate poisoning treatment, and pre-anesthetic secretion reduction. The TxGNN model predicts it may be effective for Migraine Disorder, with 0 clinical trials and 13 publications (primarily preclinical and mechanistic studies) currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Bradycardia, organophosphate poisoning antidote, pre-anesthetic secretion reduction (based on general pharmacological knowledge; no India market regulatory record available) |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.56% |
| Evidence Level | L4 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Based on established pharmacology, Atropine is a potent non-selective muscarinic acetylcholine receptor antagonist of the tropane alkaloid class. It competitively blocks acetylcholine at parasympathetic postganglionic effector sites, cardiac muscle, smooth muscle, secretory glands, and in the CNS—producing hallmark anticholinergic effects: tachycardia, reduced secretions, smooth muscle relaxation, and pupillary dilation. Detailed mechanism of action documentation from the regulatory dataset is not currently available and should be obtained from DrugBank.
The biological rationale for repurposing in migraine centres on the growing evidence that the parasympathetic nervous system plays a direct role in migraine pathophysiology. The sphenopalatine ganglion (SPG), a key intracranial parasympathetic relay, becomes activated during migraine attacks and drives neurogenic inflammation of the dura mater through vasoactive neuropeptide release. Animal research has directly demonstrated that stimulation of intracranial parasympathetic fibres triggers dural plasma protein extravasation—a hallmark of migraine-type neurogenic inflammation—suggesting that muscarinic blockade by atropine could theoretically interrupt this cascade. A clinical observation in chronic paroxysmal hemicrania (a related trigeminal autonomic cephalalgia) found that systemic atropine markedly reduced autonomic attack symptoms, offering indirect human evidence for parasympathetic involvement in this family of headache disorders.
Furthermore, the central cholinergic system modulates nociception in ways relevant to migraine. Studies in rodent models demonstrate that the antinociceptive effects of the antimigraine agent sumatriptan engage central muscarinic pathways, and atropine pretreatment attenuates these effects. However, the clinical direction of atropine’s net effect on migraine—whether beneficial or detrimental—remains entirely unvalidated. The drug’s broad CNS anticholinergic effects and narrow therapeutic window present substantial uncertainty for clinical translation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 2943405 | 1986 | Clinical observation | Cephalalgia | Systemic atropine markedly reduced attack-related sweating, tearing, and nasal secretion in chronic paroxysmal hemicrania patients, providing direct clinical evidence for parasympathetic involvement in trigeminal autonomic headache |
| 36485173 | 2024 | Animal study | Eur J Neuroscience | Cholinergic modulation (including muscarinic antagonism) and mast cell stabilisation suppressed neurogenic inflammation in a nitroglycerin-induced rat migraine model, implicating meningeal mast cell–parasympathetic crosstalk |
| 9344563 | 1997 | Animal study | Experimental Neurology | Parasympathetic sphenopalatine ganglion stimulation triggered dural plasma protein extravasation in rats, directly linking intracranial parasympathetic activation to neurogenic inflammation underlying migraine |
| 8930196 | 1996 | Animal study | J Pharmacol Exp Ther | Sumatriptan antinociception in rodents involved central cholinergic pathways; muscarinic receptor modulation affected analgesic efficacy, establishing a cholinergic component in antimigraine mechanisms |
| 10193781 | 1999 | Ex vivo | Br J Pharmacol | Atropine (3 μM) was used to isolate nicotinic-mediated relaxation in guinea pig basilar artery; findings are relevant to the vascular cholinergic mechanisms implicated in migraine headache |
| 15882801 | 2005 | Animal study | Neuroscience Letters | CGRP release from trigeminal neurons drives migraine vasodilation; nicotinic and muscarinic receptor interactions were shown to regulate centrally evoked facial blood flow changes |
| 17186568 | 2007 | Review | J Appl Toxicol | Anisodamine, a naturally occurring atropine derivative, is a non-selective cholinergic antagonist with lower CNS toxicity than atropine; review provides pharmacological context for the broader therapeutic potential of the tropane alkaloid class |
| 1786517 | 1991 | Animal study | Br J Pharmacol | Ergotamine and dihydroergotamine are potent 5-HT1C agonists in piglet choroid plexus; establishes serotonergic–cholinergic receptor interaction background relevant to antimigraine pharmacology |
| 40590589 | 2024 | Case report | Pain Medicine Case Reports | Botulinum toxin A—which shares peripheral anticholinergic mechanisms—provided effective prophylaxis for chronic migraine, providing mechanistic context for cholinergic modulation in migraine management |
| 27179636 | 2016 | Case report | Rev Port Cardiol | Atropine administered during an anaesthetic procedure led to significant autonomic dysregulation (Takotsubo syndrome); illustrates atropine’s potent systemic autonomic consequences relevant to safety evaluation in a migraine context |
India Market Information
Atropine (DB00572) has no registered product licenses in the India market at the time of this report. No authorisation numbers, dosage forms, or approved indications are on file.
Safety Considerations
Drug Interactions (380 interactions recorded; representative sample below):
Atropine’s broad anticholinergic activity gives it an extensive interaction profile. Clinically notable interactions include additive anticholinergic toxicity with agents sharing similar mechanisms, pharmacodynamic antagonism with cholinomimetics, and additive CNS/respiratory depression with opioids.
| Interacting Drug | Severity | Clinical Relevance |
|---|---|---|
| Botulinum toxin type A | Moderate | Additive peripheral anticholinergic effect; relevant as both are used near cranial structures |
| Fentanyl | Moderate | Additive CNS depression and reduced GI motility |
| Alfentanil | Moderate | Additive anticholinergic/opioid CNS and respiratory effects |
| Codeine | Moderate | Additive anticholinergic effects on GI motility |
| Dihydrocodeine | Moderate | Additive anticholinergic/opioid effects |
| Tramadol | Moderate | Additive anticholinergic and CNS effects |
| Amitriptyline | Moderate | Additive anticholinergic toxicity (tricyclic antidepressant class) |
| Galantamine | Moderate | Pharmacodynamic antagonism—atropine will block cholinesterase-inhibitor benefit |
| Acetylcholine | Moderate | Direct pharmacodynamic antagonism |
| Hyoscyamine | Moderate | Additive anticholinergic toxicity (same drug class) |
| Aclidinium | Moderate | Additive anticholinergic toxicity |
| Amantadine | Moderate | Additive anticholinergic effects |
| Chlorpheniramine / Acrivastine | Moderate | Additive anticholinergic effects (first-generation antihistamines) |
| Phenyltoloxamine | Moderate | Additive anticholinergic effects |
| Ethanol | Moderate | Additive CNS depression |
| Loperamide | Moderate | Additive reduction of GI motility |
| Acetaminophen | Minor | Delayed gastric emptying may reduce rate of absorption |
| Hydrochlorothiazide | Minor | Minor pharmacokinetic interaction |
Package insert warnings and contraindications are not available in the current dataset. Please refer to the official prescribing information for complete safety guidance before any clinical application.
Conclusion and Next Steps
Decision: Hold
Rationale: The entire evidence base for this indication consists of preclinical animal experiments, ex vivo preparations, and a single clinical observation in a related but distinct headache disorder (chronic paroxysmal hemicrania), with no registered clinical trials. While a mechanistically plausible hypothesis exists—parasympathetic/cholinergic contribution to migraine neurogenic inflammation—the clinical translation pathway is completely unvalidated, and atropine’s broad systemic anticholinergic effects pose meaningful safety uncertainties in a migraine population.
To proceed, the following is needed:
- Mechanism of action documentation from DrugBank API (currently a data gap)
- Package insert warnings and contraindications (CDSCO/TFDA label retrieval)
- Assessment of route-of-administration compatibility: current approved formulations (IV/IM/ophthalmic drops) are not practical for outpatient migraine treatment; an appropriate delivery route must be identified
- Proof-of-concept clinical data—at minimum, a pharmacodynamic pilot study measuring atropine’s effect on migraine attack frequency or severity
- Interaction review of the 380 DDI records specifically against co-medications commonly used in migraine (triptans, ergotamines, NSAIDs, beta-blockers, CGRP-targeted agents, topiramate)
- Clarification of net CNS effect direction: while peripheral parasympathetic blockade may be beneficial, central anticholinergic effects of atropine could theoretically induce cognitive side effects or even pro-nociceptive changes that complicate the therapeutic picture
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.